Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.”
The newly released white paper from the API Innovation Center highlights a critical truth: drug shortages are not isolated incidents—they are the result of a fragile and under-resourced system.
Today, more than 200 prescription medicines are in shortage nationwide, reflecting deeper structural vulnerabilities across the pharmaceutical supply chain. Limited manufacturing redundancy, global concentration of production, and long-standing economic pressures in the generic drug market have created systemic risks that can leave patients without the medicines they depend on.
The white paper brings together leaders across healthcare, manufacturing, policy, and patient advocacy to discuss solutions—and the patient voice was front and center.
Laura Bray, founder and Chief Change Maker of Angels for Change, emphasized that solving drug shortages requires collaboration across the entire healthcare ecosystem.
“This is not the patient’s job to solve at all… This is a supply chain failure.”
Bray underscored that meaningful progress depends on transparency and trust among stakeholders.
“Trust is the fuel to transparency. Transparency is the fuel to collaboration.”
The discussion also highlighted the importance of proactive tools that help identify risks before shortages reach patients. One promising solution is an early warning “stoplight” system being developed by the End Drug Shortages Alliance in collaboration with Angels for Change. The system is designed to help identify supply disruptions early—giving healthcare providers, manufacturers, and policymakers the information they need to act before patients feel the impact.
The white paper also proposes broader structural changes to strengthen resilience in the drug supply chain. These include aligning purchasing practices with reliability and quality, creating long-term demand commitments that encourage domestic manufacturing investment, and building data-driven frameworks to better measure and respond to supply chain fragility.
At Angels for Change, we believe patients and their care teams should never have to wonder whether a lifesaving medicine will be available when it’s needed most. That’s why we continue working with partners across the healthcare ecosystem to drive solutions that build a more reliable and transparent drug supply.
Read the full white paper and join the conversation:
APIIC White Paper: https://bit.ly/3P1adhZ
